| abstract |
The present invention relates to combination therapy of agents such as microtubule inhibitors, PARP inhibitors, breton kinase inhibitors or PI3K inhibitors with antibodies or immune complexes to HLA-DR or Trop-2. When using immune complexes, it is preferred to incorporate SN-38 or pro-2PDOX into them. The immune complex may be administered at a dose of 1 mg / kg to 18 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg, more preferably 8 or 10 mg / kg. Combination therapy is effective in reducing the size of solid tumors, reducing or eliminating metastases, and treating cancers that are resistant to standard therapies such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on the inhibition of tumor growth. Most preferably, the combination therapy has a synergistic effect on the inhibition of tumor growth. [Selection] Figure 2A |